Pear Therapeutics, Inc.

News Release

Pear Therapeutics to Present and Participate in a Panel at the Cowen and Company 40th Annual Healthcare Conference

February 18, 2020

Boston, February 18, 2020 – Pear Therapeutics, Inc., the leader in prescription digital therapeutics (PDTs), today announced that Corey McCann, M.D., Ph.D., President and CEO will give a corporate presentation and participate in a digital therapeutics panel discussion at the Cowen and Company 40th Annual Healthcare Conference. The presentation will be at 11:00 a.m. ET and the panel will take place at 1:30 p.m. ET on Tuesday, March 3 at the Boston Marriott Copley Place.


About Pear Therapeutics
Pear Therapeutics, Inc. is the leader in prescription digital therapeutics. We aim to redefine medicine by discovering, developing, and delivering clinically validated software-based therapeutics to provide better outcomes for patients, smarter engagement and tracking tools for clinicians, and cost-effective solutions for payers. Pear has a pipeline of products and product candidates across therapeutic areas, including severe psychiatric and neurological conditions. Our lead product, reSET®, for the treatment of Substance Use Disorder, was the first prescription digital therapeutic to receive marketing authorization from the FDA to treat disease. Pear’s second product, reSET-O®, for the treatment of Opioid Use Disorder, received marketing authorization from the FDA in December 2018. For more information, visit us at


Media and Investors:
Meara Murphy
Director, Corporate Communications